UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049178
Receipt number R000055955
Scientific Title Creating a Predictive Model of Renal Failure in Type 2 Diabetes Including Patients Taking SGLT2 Inhibitors Using Machine Learning with Artificial Intelligence.
Date of disclosure of the study information 2022/10/25
Last modified on 2025/10/14 09:26:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Creating a Predictive Model of Renal Failure in Type 2 Diabetes Including Patients Taking SGLT2 Inhibitors Using Machine Learning with Artificial Intelligence.

Acronym

Creating a Predictive Model of Renal Failure in Type 2 Diabetes Including Patients Taking SGLT2 Inhibitors Using Machine Learning with Artificial Intelligence.

Scientific Title

Creating a Predictive Model of Renal Failure in Type 2 Diabetes Including Patients Taking SGLT2 Inhibitors Using Machine Learning with Artificial Intelligence.

Scientific Title:Acronym

Creating a Predictive Model of Renal Failure in Type 2 Diabetes Including Patients Taking SGLT2 Inhibitors Using Machine Learning with Artificial Intelligence.

Region

Japan


Condition

Condition

Type 2 diabetes mellitus
Diabetic kidney disease

Classification by specialty

Endocrinology and Metabolism Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to predict the future onset of renal failure in Japanese patients with type 2 diabetes including patients taking SGLT2 inhibitors using machine learning with artificial intelligence.

Basic objectives2

Others

Basic objectives -Others

The goal is to detect high-risk groups as early as possible.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

50% reduction in eGFR from the mean value during the input period

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who attended the outpatient clinic of the Department of Nephrology, Endocrinology and Metabolism of our hospital between January 2012 and March 2022, with an eGFR of at least 30 mL/min/1.73m2 at the time of the first visit and at least two eGFR measurements every six months for at least three years.

Key exclusion criteria

None in particular

Target sample size

24187


Research contact person

Name of lead principal investigator

1st name Shu
Middle name
Last name Meguro

Organization

Keio University School of Medicine

Division name

Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine

Zip code

160-8582

Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL

03-3353-1211

Email

shumeg@keio.jp


Public contact

Name of contact person

1st name Shu
Middle name
Last name Meguro

Organization

Keio University School of Medicine

Division name

Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine

Zip code

160-8582

Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL

03-3353-1211

Homepage URL


Email

shumeg@keio.jp


Sponsor or person

Institute

Keio University School of Medicine
Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine

Institute

Department

Personal name



Funding Source

Organization

DX Business Development Department, Technology Policy Center, Corporate Research & Development, Asahi Kasei Corporation

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

DX Business Development Department, Technology Policy Center, Corporate Research & Development, Asahi Kasei Corporation

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee, Keio University School of Medicine

Address

35 Shinanomachi, Shinjuku-ku, Tokyo

Tel

03-3353-1211

Email

med-rinri-jimu@adst.keio.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 10 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

11170

Results


Results date posted


Results Delayed

Delay expected

Results Delay Reason

Under analysis

Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2022 Year 09 Month 08 Day

Date of IRB

2022 Year 09 Month 08 Day

Anticipated trial start date

2022 Year 11 Month 01 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2027 Year 03 Month 31 Day


Other

Other related information

Using an anonymized medical information database of patients in the Department of Nephrology, Endocrinology and Metabolism at Keio University Hospital, we will investigate whether it is possible to predict renal prognosis based on features from the variable components of eGFR, urinary protein, oral medicine including SGLT2 inhibitors, using machine learning methods based on artificial intelligence.


Management information

Registered date

2022 Year 10 Month 11 Day

Last modified on

2025 Year 10 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000055955